Arcellx, Inc.

Listed Company

ACLXCIK 0001786205NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$22.29M

Net Income

$-228.93M

Total Assets

$603.99M

Equity

$402.35M

Shares Out

58.48M

Op. Cash Flow

$-210.26M

Business

Arcellx, Inc. is a clinical-stage biotechnology company developing engineered cell therapies using its proprietary D‑Domain binding scaffold. Its main products include D‑Domain–powered single‑infusion ddCARs (e.g., BCMA‑targeting anito‑cel) and dosable, universal ARC‑SparX systems combining ARC‑T cells with SparX adapter proteins for controllable targeting. The company organizes activities across ddCAR and ARC‑SparX platforms, preclinical discovery, and clinical development programs (multiple myeloma, AML/MDS, solid tumors, and autoimmune indications) and collaborates with partners for development and manufacturing. Arcellx conducts clinical trials primarily in the United States and pursues global development and commercialization through partnerships and clinical sites internationally.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue from related party	22	108	110	—	—
Research and development	158	157	134	150	47
General and administrative	118	88	66	42	18
Total operating expenses	275	246	200	191	65
Loss from operations	−253	−138	−90	−191	−65
Interest and other income (expense)	24	33	24	4	—
Interest expense	0	−1	−4	−2	−10,000
Total other income, net	24	32	20	3	49,000
Loss before income taxes	−229	−105	−70	−189	—
Income tax expense	−69,000	−2	−663,000	—	—
Net loss	−229	−107	−71	−189	−65
Unrealized gain (loss) on marketable securities	−5,000	301,000	768,000	−201,000	20,000
Comprehensive loss	−229	−107	−70	−189	−65
Net loss per share attributable to common stockholders - basic	−4.07	−2	−1.47	−5.19	−145.55
Net loss per share attributable to common stockholders - diluted	−4.07	−2	−1.47	−5.19	−145.55
Weighted-average common shares outstanding - basic	56	54	48	36	446,379
Weighted-average common shares outstanding - diluted	56	54	48	36	446,379

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	80	106	395	64	31
Marketable securities	370	482	307	191	74
Restricted cash, current	0	208,000	2	0	—
Prepaid expenses and other current assets	12	12	12	12	8
Total current assets	462	599	716	267	113
Restricted cash, non-current	3	2	2	3	199,000
Marketable securities, non-current	70	38	27	0	—
Property and equipment, net	43	46	43	11	10
Operating lease right-of-use assets	24	24	27	29	3
Prepaid research and development expenses and other long-term assets	3	1	9	5	2
Total assets	604	711	825	314	129
Accounts payable	6	2	3	9	1
Accrued liabilities	35	57	18	12	13
Operating lease liabilities, current portion	8	7	8	3	—
Finance lease liabilities, current portion	0	230,000	39	33	—
Contract liability to related party	56	59	51	—	—
Total current liabilities	104	125	118	57	15
Operating lease liabilities, net of current portion	44	47	51	31	—
Contract liabilities, net of current portion to related party	53	76	171	0	—
Other non-current liabilities	0	9	—	—	178,000
Total liabilities	202	257	340	109	17
Commitments and Contingencies (Note 11)	—	—	—	—	—
Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 57,929,325 shares issued and outstanding as of December 31, 2025; 1,000,000,000 shares authorized and 54,293,597 shares issued and outstanding as of December 31, 2024	56,000	53,000	52,000	44,000	1,000
Additional paid-in capital	1,127	951	874	524	9
Accumulated other comprehensive income	843,000	848,000	547,000	−221,000	−20,000
Accumulated Deficit	−726	−497	−389	−319	−130
Total stockholders' equity	402	455	485	−205	−122
Total liabilities and stockholders' equity	604	711	825	314	129

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	7	5	2	1	1
Loss on disposal of property and equipment	82,000	−260,000	174,000	3,000	3,000
Noncash operating lease expense	−38,000	3	1	—	—
Right of use asset expensed	0	794,000	19	63	—
Amortization of premiums and discounts on marketable securities	−8	−15	−11	−2	210,000
Share-based compensation	78	61	42	22	7
Prepaid expenses and other current and non-current assets	−2	9	−8	−6	−6
Accounts payable and other current liabilities	3	−70,000	−6	7	974,000
Accrued liabilities	−21	42	6	−395,000	8
Operating lease liabilities	−2	−4	13	3	—
Contract liability to related party	−26	−86	221	—	—
Other non-current liabilities	−9	9	0	—	—
Net cash provided by (used in) operating activities	−210	−83	208	−99	−54
Purchases of property and equipment	−2	−13	−21	−2	−6
Purchases of marketable securities	−407	−597	−442	−274	−74
Proceeds from maturities of marketable securities	496	428	309	158	—
Net cash provided by (used in) investing activities	86	−183	−155	−118	−80
Proceeds from issuance of common stock in private placement, net of transactions costs	0	0	300	10	—
Proceeds from issuance of common stock in offerings, net of issuance costs	132	0	0	129	—
Proceeds from exercise of stock options	4	15	8	—	—
Proceeds from issuance of common stock under the employee stock purchase plan	1	1	1	—	—
Payments under finance leases	−230,000	−40	−29	−10	—
Tax withholding payments related to net share settlement of restricted stock units	−38	0	0	—	—
Net cash provided by (used in) financing activities	99	−24	279	253	118
Net increase (decrease) in cash and cash equivalents and restricted cash	−25	−291	332	36	−16
Cash paid for income taxes	1	2	212,000	—	—
Purchase of property and equipment included in accounts payable and accrued liabilities	944,000	325,000	2	770,000	278,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro